Characteristics and Cholesterol Treatment of Patients With Atherosclerotic Cardiovascular Disease (ASCVD), Familial Hypercholesterolaemia, and Those Otherwise at Moderate/High-Risk of ASCVD in Australian Primary Care (SCOPE-GP)

A. Tonkin, R. Audehm, C. Hespe, D. Liew, P. Berry, K. Chin, M. Rahman, R. Santani, C. Sciascia, G. Watts

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Background Little information exists on the proportion and characteristics of Australian primary care patients not attaining low-density lipoprotein cholesterol (LDL-C) goals. This study sought to describe characteristics, LDL-C levels, and treatment patterns in patients with atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolaemia (FH) and those otherwise at moderate/high risk of ASCVD. Methods This population-based retrospective cohort study used de-identified medical records of adult patients captured in the IQVIA GP-EMR database from 1 January 2010 to 30 June 2022. Ascertainment of study cohort was based on the 2021 ESC/EAS guidelines and Framingham Risk Equation in use at the time of data collection. LDL-C levels were recorded at the patient’s last visit/censor date. Results In ASCVD patients, 51.8% (n=7,080) had recorded LDL-C levels, of which 33.8% and 8.2% were ≥1.8 mmol/L and <1.4 mmol/L, respectively. A total of 33.1% had no lipid lowering therapy (LLT) recorded from index to 30 June 2022. 46.1% (n=37,773) of moderate-risk and 45.3% (n=81,448) of high-risk subjects had recorded LDL-C levels. Among these patients, 39.0% vs 34.5% were ≥1.8 mmol/L, and 69.3% vs 58.4% were not receiving any LLT. In FH patients, 46.6% (n=230) had LDL-C levels recorded; of these patients, 43.81% were >2.0 mmol/L and 1.42% between 1.8 to ≤2.0 mmol/L. 46.0% had no LLT recorded and 12.6% were on statin+ezetimibe. Conclusion Most patients with ASCVD, FH or otherwise at moderate/high-risk of ASCVD did not attain LDL-C goals and appear to be suboptimally treated with LLT. Additionally, almost half of each group had no recorded LDL-C levels, highlighting a gap in their monitoring and management.

Original languageEnglish
Article number845
Pages (from-to)S514-S515
Number of pages2
JournalHeart Lung and Circulation
Volume33
Issue numberSupplement 4
DOIs
Publication statusPublished - Aug 2024
EventCardiac Society of Australia and New Zealand Annual Scientific Meeting 2024 - Perth Convention and Exhibition Centre, Perth, Australia
Duration: 1 Aug 20244 Aug 2024
Conference number: 72nd
https://www.heartlungcirc.org/issue/S1443-9506(24)X0013-X (abstracts published in Journal supplement)
https://www.csanzasm.com/ (Conference website)

Cite this